INTRODUCTION
Reversible protein phosphorylation plays a critical role in cell physiology, and dysregulation of the mechanisms that control specific phosphorylation events contributes directly to disease. Indeed, inappropriate kinase activation plays a causal role in most cancers, and we now understand the role of several kinase oncogenes in programming the malignant phenotype (Broach and Levine, 1997; Hanahan and Weinberg, 2000) . In contrast, much less is known concerning the function of phosphatases in cancer development.
Studying transformation in human cell culture models has helped elucidate pathways related to spontaneous cancer development . We previously demonstrated that ectopic expression of the telomerase catalytic subunit (hTERT), the SV40 Early Region (SV40 ER), and an oncogenic allele of H-RAS confers a tumorigenic phenotype to several types of normal human cells (Zhao et al., 2004) . Subsequent work has now defined combinations of cancer-associated mutations that suffice to transform human cells (Boehm et al., 2005; Drayton et al., 2003; Seger et al., 2002) . Indeed, the SV40 ER encodes two oncoproteins, the SV40 large T (LT) and small t (ST) antigens. LT binds the retinoblastoma and p53 proteins and in turn inactivates these two tumor suppressor pathways (Ali and DeCaprio, 2001) , activities central to its role in human cell transformation Voorhoeve and Agami, 2003) .
ST binds the serine-threonine protein phosphatase 2A (PP2A), and this interaction is essential for ST to transform cells Sugano et al., 1982; Yu et al., 2001) . The viral oncoproteins SV40 ST, the small and middle T antigens of polyoma virus, and the adenoviral protein E4orf4 all bind PP2A [reviewed in (Schonthal, 2001) ], suggesting that like other targets of viral oncoproteins, PP2A plays an important role in tumor suppression (Pallas et al., 1990; . The involvement of PP2A in transformation is also supported by the observation that the PP2A inhibitor, okadaic acid (OA), is a potent tumor promoter (Suganuma et al., 1988) .
PP2A comprises a family of ubiquitously expressed serine-threonine phosphatases implicated in regulation of many signaling pathways. PP2A holoenzymes are composed of three subunits, a catalytic C subunit, a structural A subunit, and a regulatory B subunit. Each of these subunits is encoded by several distinct genes, which are assembled to create numerous ABC holoenzymes [reviewed in (Janssens and Goris, 2001) ]. The large number of different PP2A heterotrimers suggests that specific regulatory subunits mediate particular physiological functions.
Suppressing the expression of the PP2A B56g regulatory subunit or partially depleting the structural Aa subunit cooperates with LT, hTERT and H-RAS to convert human cells to tumorigenicity (Chen et al., , 2004 . Although mutations of PP2A Aa occur at low frequency in human tumors (Calin et al., 2000) , mutations of the second PP2A A subunit, Ab, are more common (Calin et al., 2000; Ruediger et al., 2001a; Takagi et al., 2000; Tamaki et al., 2004; Wang et al., 1998) . Specifically, somatic mutations of Ab, including point mutations, deletions, frameshifts, and splicing abnormalities, have been found in 8%-15% of colon cancers, 15% of lung cancers, 13% of breast cancers, and 6% of tumor cell lines (Calin et al., 2000; Ruediger et al., 2001a; Takagi et al., 2000; Tamaki et al., 2004; Wang et al., 1998) . These cancerassociated PP2A Ab mutants are defective in binding to B and/or C subunits in vitro (Ruediger et al., 2001a) . In addition to mutations, the PP2A Ab gene is located at 11q23, a chromosomal region frequently deleted in human cancers (Baysal et al., 2001) . Moreover, reduced expression of the PP2A Ab subunit has been found in 16 of 32 cancer cell lines derived from human lung, colon, breast, and cervical carcinomas (Zhou et al., 2003) . While these observations implicate PP2A Ab as a tumor suppressor gene, the mechanism by which Ab loss of function contributes to tumor development remains undefined. Here we assess the impact of Ab dysfunction in human cell transformation and identify RalA as an interacting effector protein regulated by PP2A Ab complexes.
RESULTS

Suppression of PP2A Ab Expression Transforms Human Cells
To assess the role of PP2A Ab structural subunit in human cell transformation, we suppressed Ab expression in immortal, nontumorigenic HEK cells expressing LT, hTERT, and H-RAS (HEK TER) cells using a short hairpin RNA (shRNA) specific for Ab (shAb). Introduction of shAb into HEK TER cells overexpressing FLAG-tagged PP2A Ab led to suppression of the ectopically expressed Ab ( Figure 1A ). We then generated HEK TER cell lines that stably harbored either shAb (HEK TER-shAb) or a control shRNA targeting GFP (shGFP) (HEK TER-shGFP). Expression of shAb in HEK TER cells reduced Ab mRNA levels by 78 ± 6% compared to those found in control cells ( Figure 1B) .
In parallel, we generated a HEK TER cell line expressing shRNA targeting the other structural PP2A A subunit (Aa) ( Figure 1C) . Suppression of the PP2A Aa subunit resulted in a substantial reduction of the levels of the PP2A B55a and B563 regulatory subunits and the catalytic Ca subunit ( Figure 1C , left panels). These observations corroborate prior work that demonstrated that the PP2A regulatory and catalytic subunits exhibit limited stability when not bound to a structural PP2A A subunit (Silverstein et al., 2002) . In contrast, suppressing PP2A Ab expression failed to alter the levels of these regulatory and catalytic PP2A subunits ( Figure 1C , right panels). In consonance with these findings, we observed that PP2A-attributable phosphatase activity was decreased by 80 ± 6% or 13 ± 3% in cells expressing shAa or shAb, respectively, compared to control shGFP cells ( Figure 1D ). These findings confirm previous observations (Hemmings et al., 1990; Zhou et al., 2003) that concluded that PP2A complexes containing Ab represent a small fraction of the total PP2A complexes.
We next examined the effects of suppressing either PP2A Aa or Ab on proliferation, anchorage-independent (AI) growth and tumor formation. Consistent with our prior work , we found that HEK TER cells expressing very low levels of Aa proliferated poorly and failed to grow in an AI manner or to form tumors ( Figures  1E, 1F , and S1D in the Supplemental Data available with this article online). In contrast, suppression of the PP2A Ab subunit induced a small increase in the rate of proliferation ( Figure 1E ), conferred the ability to grow in an AI manner, and permitted these cells to form tumors (Figures 1F and S1A) .
To exclude the possibility that these observations were due to off-target effects of RNAi, we used a second shRNA that targets a different region of the PP2A Ab mRNA (shAb-2). This second shRNA also efficiently suppressed Ab expression in HEK TER cells and permitted these cells to grow in an AI manner (Figures S1B and S1C). Overexpression of a PP2A Ab allele resistant to suppression by shAb ( Figure S1D ) reversed the observed transformed phenotype ( Figures 1G and 2B ). Moreover, we found that suppression of Ab expression in immortal, human small airway epithelial cells expressing hTERT, LT, and H-RAS (AATER cells) (Lundberg et al., 2002) also permitted AI growth ( Figure 1G ), indicating that the observed effects of suppressing Ab are not restricted to a particular cell type. Together, these results suggest that loss of PP2A Ab expression contributes directly to cell transformation.
Cancer-Associated PP2A Ab Mutants Are Functionally Defective Mutations in PP2A Ab are found in lung, breast and colon cancers and include missense mutations involving P65S, L101P, V448A, V545A, G8R, K343E and L101P/V448A (Wang et al., 1998) . In addition, one PP2A Ab mutation involves the deletion of exon 9, resulting in an in-frame deletion of 45 amino acids (DE344-E388). To study the function of these cancer-associated mutants, we generated FLAG-epitope tagged versions of wild-type (WT) PP2A Ab or cancer-derived Ab mutants. We overexpressed these Ab alleles in HEK TER cells and determined whether such Ab mutants formed functional PP2A complexes. In Ab immune complexes, we found that the WT PP2A Ab subunit formed heterotrimers with the catalytic Ca and each of the regulatory B subunits tested ( Figures  2A, S2A , and S2B). In contrast, each of the cancer-derived Ab mutants showed clear defects in their ability to form productive PP2A complexes (Figure 2A , lower panel, and Figures S2A-S2C ), corroborating a prior report (Ruediger et al., 2001a) .
We next determined whether these Ab mutants retained phosphatase activity by measuring PP2A Ab-attributable phosphatase activity in Ab immune complexes isolated from HEK TER cells expressing WT or mutant PP2A forms of Ab (Figure 2A ). We found that the phosphatase activity associated with mutant Ab (P65S, V545A, G8R, K343E or D504G) immune complexes was reduced by 48 ± 5%, 70 ± 7%, 68 ± 9%, 52 ± 4%, or 71 ± 9% respectively, compared to the activity levels found with the WT Ab subunit. We failed to detect any Ab-attributable phosphatase activity in cells expressing the Ab mutants L101P/V448A, DE344-E388, L101P, and V448A ( Figure 2A ). Thus, we concluded that cancer-associated mutations of PP2A Ab mutants fail to form the full compliment of PP2A complexes and demonstrate impaired mutant-specific phosphatase activity.
Loss-of-Function of Both Ab Alleles Is Necessary to Transform Human Cells
To determine whether Ab mutants exhibit gain of function properties, we measured the total PP2A-specific phosphatase activity in cells overexpressing WT Ab or Ab mutants. Introduction of WT Ab or the P65S or G8R Ab mutants resulted in a slight increase in total phosphatase activity, while no changes in overall activity were found in cells expressing other Ab mutants ( Figure S3 ). Thus, PP2A Ab mutants did not disrupt endogenous phosphatase activity by acting as dominantly acting negative alleles. Moreover, introduction of the WT allele of PP2A Ab or any of the mutant PP2A Ab alleles into immortalized but nontumorigenic HEK TER cells failed to transform these cells, confirming that these mutations fail to act as dominant oncogenes (data not shown).
In consonance with these observations, Ab mutant alleles are usually accompanied by the deletion of the second allele in human tumor samples (Tamaki et al., 2004; Wang et al., 1998) . To mimic this situation, we generated WT and mutant alleles of Ab (RAb) that are resistant to targeting by shAb and expressed them in HEK TERshAb cells (Figures S1D and 2B, lower panel) . We found that expression of the WT PP2A Ab (RAb) in tumorigenic HEK TER-shAb cells decreased cell proliferation by 36% ( Figure S4A ). In contrast, expression of each of the Ab mutants failed to alter substantially the proliferation rate of shAb cells ( Figure S4A ). Introduction of RAb in HEK TER-shAb or AATER-shAb cells also significantly .
(E) AI growth of cell lines indicated in C. *p < 0.0008 and **p < 0.0019 as determined using the Student's t test.
(F) Kinetics of tumor growth of H2009 and H1450 cells expressing a control vector or WT Ab. 6 xenografts for each cell line were studied. *p < 0.83 and **p < 0.039 as determined by ANOVA. V, control vector. Mean ± SD for three independent experiments are shown in bar and line graphs.
suppressed AI growth (62% ± 8% and 67% ± 9%, respectively) and reduced the number of tumors formed, whereas introduction of other Ab mutants showed no inhibitory effects on the transformed phenotype ( Figures  1G, 2B , and S4B). These observations confirmed that each of cancer-associated PP2A Ab mutants is a functionally null allele and that loss-of-function of both Ab alleles is necessary to induce a fully transformed phenotype.
Restoration of Ab Function in Lung Carcinoma Cells Reverses the Tumorigenic Phenotype
To investigate the role of PP2A Ab mutations in patientderived cancer cell lines, we determined the effects of restoring PP2A Ab function in lung cancer cell lines that harbor PP2A Ab mutations. The H1450 and H838 lung cancer cell lines harbor PP2A Ab subunit mutations (Wang et al., 1998) . The H1450 cell line carries one Ab allele containing an in-frame deletion of residues 717-1583 and a second allele with point mutation D504G, while H838 harbors only one mutant Ab allele (G8R). To examine whether expression of the Ab subunit reverses the tumorigenic phenotype, we introduced the WT Ab allele into these lung cancer cell lines harboring mutant PP2A Ab ( Figure 2C ). As control, we used the primary AATER cells and two lung carcinoma cell lines -H1437 that harbors two WT Ab alleles and H2009 that has one WT Ab allele and a G90D Ab allele. When overexpressed, the Ab G90D allele behaved in a manner indistinguishable from WT Ab with regard to forming active PP2A complexes and suppressing AI growth (data not shown). Expression of WT Ab in the H1450 and H838 cell lines suppressed their doubling rate by 68% ± 8% and 58% ± 9%, respectively (Figures 2C and 2D and Table 1 ) and reduced the number of AI colonies formed by these cell lines by 77 ± 8% and 42 ± 5%, respectively ( Figure 2E ).
Moreover, expression of WT Ab into H1450 significantly suppressed tumor growth ( Figure 2F ). In contrast, introduction of WT Ab into the H1437, H2009 or AATER cell lines, each of which carries a WT Ab allele, failed to inhibit cell proliferation, AI growth or tumor growth, suggesting that the decreased cell proliferation and AI growth observed in H1450 and H838 cells was not an artifact induced by overexpression of Ab (Figures 2C-2F and Table 1 ).
Cell cycle analysis by double 5-bromo,3 0 -deoxyuridine/ propidium iodide (BrdU/PI) staining showed that the introduction of WT Ab into H838 and H1450 cells increased the percentage of cells present in the G1 phase of the cell cycle (Table 1) . In contrast, expression of WT Ab failed to affect the cell cycle distribution of AATER, H1437 and H2009 cells. In all of these cells, we did not detect any evidence of increased numbers of apoptotic cells after overexpression of WT Ab ( Table 1 ), suggesting that the decreased proliferative rate induced by WT Ab in lung carcinoma cell lines harboring mutant Ab was due to the lengthening of cell cycle rather than apoptosis.
Suppression of PP2A Aa or Ab Induces Transformation by Distinctive Mechanisms
We previously reported that partial suppression of PP2A Aa imparts a tumorigenic phenotype ( Figure 3A ) by selectively eliminating PP2A B56g containing complexes (Chen et al., 2004) . Although the two distinct PP2A A isoforms, Aa and Ab, share 86% sequence identity (Hendrix et al., 1993) , it remained unclear whether these isoforms share overlapping functions. To determine if Aa and Ab were interchangeable, we overexpressed Aa in HEK TER cells in which we suppressed Ab expression (HEK TER-shAb). Overexpression of PP2A Aa in these cells failed to revert the transformed phenotype induced by Ab suppression, indicating that the Aa isoform does not functionally AALER-V 55 ± 9 55.4 ± 9.3 22.5 ± 4.3 22.1 ± 3.6 4.5 ± 0.5 AALER-Ab 58 ± 8 58.3 ± 7.7 20.4 ± 3.1 21.3 ± 2.3 4.6 ± 0.3 H1437-V 21 ± 3 33.5 ± 5.3 42.6 ± 5.6 23.9 ± 2.5 2.3 ± 0.5 H1437-Ab 41 ± 5 35.5 ± 4.4 45.9 ± 4.2 18.8 ± 2.4 3.5 ± 0.8 H2009-V 24 ± 3 51.3 ± 5.7 28.5 ± 2.7 20.2 ± 4.9 5.3 ± 0.6 H2009-Ab 25 ± 1 53.5 ± 6.8 27.7 ± 1.8 19.9 ± 2.9 4.9 ± 0.5 H1450-V 20 ± 4 40.3 ± 5.5 33.5 ± 2.7 26.2 ± 4.7 5.3 ± 0.6 H1450-Ab 53 ± 6 73.5 ± 9.6** 8.7 ± 1.8** 17.8 ± 2.9 4.9 ± 0.5 H838-V 22 ± 3 46.7 ± 6.6 36.4 ± 5.2 16.9 ± 2.6 3.8 ± 0.4 H838-Ab 41 ± 6 75.3 ± 6.8** 8.9 ± 1.2** 15.8 ± 2.3 4.1 ± 0.5
Proliferation rate of lung carcinoma cell lines expressing a control vector (V) or wild-type Ab was analyzed as described in Supplemental Experimental Procedures. Cell-cycle distribution of these cells was determined by analysis of BrdU/PI stained cells. Apoptosis level was measured by analysis of double Annexin V/PI-stained cells. Data shown as mean ± SD. **p < 0.01 was determined using the Student's t test.
substitute for loss of Ab expression ( Figure 3A ). Consistent with these observations, we confirmed that only the PP2A Aa isoform forms complexes with ST (Zhou et al., 2003) ( Figures 3B and S5 ). These observations indicate that suppression of Ab induces transformation by a mechanism distinct from that caused by partial depletion of PP2A Aa or by expression of ST.
The Small GTPase RalA Interacts with PP2A Ab To study the mechanism by which PP2A Ab suppression contributes to transformation, we purified PP2A Aa and Ab complexes to identify proteins that bind uniquely to Ab. Specifically, we overexpressed FLAG-epitope tagged forms of Aa and Ab in 293T cells, isolated the immune complexes formed with these proteins ( Figure 3C ) and identified proteins that associate with the Aa and Ab subunits by mass spectrometry ( Figure S6 ). We found that the PP2A catalytic Ca and several regulatory B subunits associated with both the Aa-and Ab-specific complexes, confirming that these conditions permitted the isolation of functional heterotrimers (Figures 3C and S6A) . Although most proteins identified by this approach interacted with both Aa and Ab, we found a small number of proteins that bound only to PP2A Ab. When we attempted to verify these putative Ab interacting proteins, we found that the small GTPase protein RalA was the only protein that specifically formed complexes with Ab subunit (Figures 3D and S6B) . RalA has been implicated in the regulation of exocytosis, transcription, secretion, cell transformation and tumor progression [reviewed in (Feig, 2003; Feinstein, 2005) ]. When we overexpressed HA-tagged-RalA and FLAGtagged Ab in 293T cells, we found that immune complexes isolated using either HA-or FLAG-specific antibodies contained both RalA and Ab ( Figure 3E ). We also found that endogenous RalA interacts with FLAG-tagged Ab in 293T cells ( Figure 3D ) and that both RalA and Ab were found in membrane fraction of HEK TER-Ab cells ( Figure S7A ). In contrast, PP2A Aa failed to form complexes with RalA ( Figures 3D and 3E) , confirming that RalA binds specifically PP2A Ab-containing complexes. We note that RalA-Ab complexes were comprised of 16 ± 5% of the total RalA and 9 ± 2% of the total Ab proteins ( Figure S7B ). These observations indicate that the interaction between the PP2A Ab complex and RalA involves a small fraction of the total PP2A Ab complexes and RalA and suggests that these interactions are likely short-lived as would be expected for interactions between phosphatases and their substrates.
We then determined whether cancer-associated Ab mutants form complexes with RalA by purifying PP2A Ab immune complexes from HEK TER cells expressing WT Ab or cancer-associated Ab mutants (G8R, V454A, and V448A) representing each of the categories defined in Figure S2C . WT Ab but not Ab point mutants bound endogenous RalA ( Figure 3F ). This observation makes it unlikely that interaction between WT Ab and RalA is nonspecific and suggests that loss of Ab function also impairs RalA complex formation.
RalA Is Necessary for Transformation Induced by PP2A Ab Suppression To assess whether RalA expression was required for cell transformation induced by loss of Ab expression, we suppressed RalA expression using two different RalA-specific shRNAs (shRalA-1 and shRalA-2) ( Figure 4A , upper panel). Immunoblotting with a RalA-specific antibody revealed that both shRalA-1 and shRalA-2 efficiently suppressed RalA expression. Suppression of RalA inhibited the proliferation of HEK TER cells expressing shGFP ( Figure 4A ). In contrast, suppression of RalA failed to affect the proliferation rate of the HEK TER-shAb, HEK TER-LowAa, and HEK TER-ST cell lines. These findings are consistent with prior observations that showed that RalA is not limiting for serum-dependent proliferation of tumorigenic cells under standard culture conditions (Chien and White, 2003) .
To examine the contribution of endogenous RalA to oncogenic transformation, we then tested the consequences of suppressing RalA expression on AI growth. Depletion of RalA inhibited the ability of HEK TER cells expressing shAb to form AI colonies by 94% ± 5% ( Figure 4B ). In contrast, suppression of RalA in HEK TER cells expressing ST or in which Aa expression was decreased by 50% (LowAa) only partially inhibited the ability of these cells to form AI colonies (37% ± 6% and 61% ± 6%, respectively) ( Figure 4B ), consistent with prior observations that showed that oncogenic alleles of H-RAS also activate RalGEFs (Lim et al., 2005) . These findings indicate that RalA expression is necessary for the transformed phenotype induced by suppression of Ab.
PP2A Ab Negatively Regulates RalA Activity
To determine whether the interaction of Ab with RalA perturbs RalA function, we examined RalA activity in HEK TER cells in which Ab expression was suppressed. RalA activity was analyzed by determining the amount of GTP-bound, and therefore active, RalA bound to recombinant Ral-BP1 protein. We found a 4.5-fold increase in GTP-bound RalA levels in cells lacking Ab compared to control cells expressing shGFP ( Figure 4C ). Expression of ST or partial suppression of Aa had no effect on the steady state amount of GTP-bound RalA ( Figure 4C ), consistent with our prior observations that suggested that Ab induces transformation by a mechanism distinct from that caused by partial inhibition of Aa or ST overexpression.
In contrast, introduction of exogenous PP2A Ab inhibited RalA activity in both HEK TER and HEK TERshAb cells as measured by decreased levels of GTPbound RalA ( Figure 4D ). To test whether cancer-derived Ab mutants affected RalA activity, we overexpressed the shRNA-resistant G8R Ab mutant in HEK TER cells lacking Ab expression. We found that the G8R Ab mutant that cannot form complexes with RalA ( Figure 3F ) also failed to affect RalA activity ( Figure 4D ). Consistent with these findings, the H838 lung cancer cell line that harbors a single mutant Ab allele exhibited approximately 4-fold higher levels of RalA activity compared to the H2009 carcinoma cell line that harbors WT Ab ( Figure 4D ). Overexpression of WT Ab in both H838 and H2009 cell lines decreased the amount of GTP-bound RalA identified using this Ral-BP1 binding assay. Moreover, introduction of WT PP2A Ab into H838 cells decreased the amount of activated RalA to the level found in H2009 cells ( Figure 4D ). Together, these experiments indicate that the interaction of Ab with RalA inhibits RalA activity.
PP2A Ab Dephosphorylates RalA
We next determined whether PP2A Ab complexes dephosphorylate RalA. Using a phospho-serine specific antibody, we found the accumulation of a serinephosphorylated form of RalA in cell lines in which Ab expression was suppressed ( Figure 5A ). This observation suggested that RalA was a direct substrate for Ab PP2A complexes.
A prior report indicated that RalA can be phosphorylated by Aurora A kinase at Ser194 (Wu et al., 2005) . To identify other potential RalA phosphorylation site(s), we isolated RalA from HEK TER-shAb cells and performed a mass spectrometric analysis. Although we obtained highly redundant coverage of most of the RalA protein, peptides corresponding to the carboxyl-terminal portion of the protein were underrepresented. This portion of RalA is highly basic and contains a prenylation site. Of the portion of RalA that we were able to assess, we found evidence of RalA phosphorylation at Ser11 and Ser183 (data not shown) but no other serine or threonine residues.
To determine whether any of these serine residues were the target of Ab-containing PP2A complexes, we replaced each of these three serine residues with alanine and generated HA-tagged S11A, S183A and S194A RalA mutants. We co-expressed these RalA alanine substitution mutants and FLAG-tagged Ab in 293T cells and determined whether these RalA mutants retained the ability to bind Ab ( Figure 5B ). We found that Ab bound to both WT RalA and the S11A RalA mutant. In contrast, the S183A and S194A RalA mutants showed diminished ability to form complexes with Ab ( Figure 5B ). These observations suggested that PP2A Ab binds to and dephosphorylates RalA at Ser183 and Ser194.
To confirm these observations, we created antibodies that recognize RalA phosphorylated at Ser183/Ser194 by immunizing mice with two KLH-conjugated phosphopeptides (phospho-Ser183 and phospho-Ser194). We found that the sera from one of these immunized mice and several hybridoma supernatants derived from this immunized mouse contained antibodies specific for RalA phosphorylated at Ser183 and Ser194 (Figures 5C, and S8A-S8C). Specifically, sera from one of the immunized mice harbored antibodies that recognized both phosphorylated and nonphosphorylated forms of RalA. One hybridoma line derived from this mouse (XL13), bound only phosphorylated RalA.
We then used these phospho-specific antibodies to determine whether Ser183 and Ser194 in RalA were targets of PP2A Ab. In cells lacking the expression of Ab, a condition where we previously found evidence for increased RalA activity, these antibodies recognized higher levels of phosphorylated RalA, compared to cells expressing Ab. To verify the specificity of these antibodies, we treated RalA immune complexes with calf intestinal phosphatase (CIP), which eliminated the RalA species detected by these phosphospecific antibodies without affecting total RalA levels ( Figures S8A-S8C) . Moreover, when we overexpressed WT RalA and S183A, S194A and S183/194A RalA mutants in HEK TER cells lacking Ab expression (HEK TER-shAb), we found that the S183A and S194A RalA mutants showed decreased levels of phosphoRalA compared to WT RalA. Importantly, we failed to detect phosphorylated RalA in cells expressing the double S183/194A RalA mutant with these phosphospecific Interaction between Ab and RalA mutants. FLAG-tagged Ab and HA-tagged RalA (wild-type wt, S11A, S183A, S194A) were expressed in 293T cells. Ab-specific complexes were isolated using anti-Flag agarose followed by immunoblotting using FLAG or RalA specific antibodies. (C) Detection of RalA phosphorylation at Ser183 and Ser194. Control vector (vector), WT RalA and S11A, S183A, S194A and S183/194A RalA mutants were overexpressed in HEK TERV and HEK TER-shAb cells and HA-immune complexes isolated. Immunoblotting was performed sera form mice immunized with phospho-Ser183 RalA and phospho-Ser194 RalA peptides (IMS), XL13 hybridoma supernatant, or FLAG (M2) antibodies. (D) Phospho-RalA expression levels were analyzed in the membrane fraction of lung carcinoma cell lines (H1437, H2009, H1450 and H838). Immunoblotting was performed XL13 hybridoma supernatant or FLAG (M2) antibodies (total RalA). (E) Activity of RalA alanine substitution mutants. Amount of GTP-bound RalA was determined in HEK TER-shAbÀshRalA cells expressing shRNAresistant forms of RalA. (F) AI growth and tumor formation of HEK TER-shAb-shRalA cells expressing shRalA-resistant RalA alanine substitution mutants. shRalA-resistant forms of WT RalA and RalA mutants were expressed in HEK TER-shAbÀshRalA cells. The number of AI colonies formed is presented as the mean ± SD for three independent experiments. Tumors are reported as number of tumors formed per number of injection sites.
antibodies ( Figure 5C ). These observations confirmed that Ser183 and Ser184 in RalA are the targets of PP2A Abcontaining complexes.
We then analyzed phospho-RalA levels in lung cancer cell lines harboring Ab mutations. Phosphorylated forms of RalA were undetectable in the H1437 and H2009 cell lines that harbor WT Ab. In contrast, we found that RalA was phosphorylated in H838 and H1450 cell lines that lack functional Ab alleles ( Figure 5D ). Together, these studies strongly implicated Ser183 and Ser194 in RalA as substrates of PP2A complexes containing Ab.
To determine whether the phosphorylation state of RalA contributes to transformation induced by loss of Ab function, we created S183A and S194A RalA mutants resistant to the RalA-specific shRNA by introducing silent substitutions into the RalA coding sequence ( Figure S8D ). We overexpressed these shRNA-resistant RalA mutants in HEK TER cells in which both RalA and Ab were suppressed (HEK TER-shAb-shRalA). The overexpression of WT RalA or the S11A RalA mutant restored RalA activity while expression of the S194A or S183A RalA mutants was unable to complement the suppression of endogenous RalA ( Figure 5E ). These observations suggest that PP2A Ab-mediated dephosphorylation of RalA at Ser183 and Ser194 down-regulates its activity. Consistent with these observations, suppression of RalA in HEK TERshAb cells inhibited AI growth and tumor formation, and expression of a shRalA-resistant form of WT RalA or the S11A RalA mutant restored the tumorigenic phenotype caused by Ab suppression ( Figure 5F ). In contrast, overexpression of shRalA-resistant S183A or S194A RalA mutants failed to reverse the transforming phenotype induced by loss of Ab expression. Together, these observations implicate the control of phosphorylation of RalA at Ser183 and Ser194 by PP2A Ab as a critical regulatory step in RalA function.
DISCUSSION
PP2A Aa and Ab: Distinct Tumor Suppressor Complexes
Several PP2A complexes have been implicated in cancer development (reviewed in Schonthal, 2001 ). The observation that mutations of the PP2A Ab structural subunit occur in many human tumors suggested that this subunit participates in malignant transformation. Here we show that Ab loss-of-function cooperates with the expression of LT, hTERT and H-RAS to convert human cells to a transformed phenotype. Moreover, that the introduction of a WT Ab allele into lung cancer cell lines carrying loss-of-function Ab mutations partially reversed the tumorigenic phenotype of these cells. These findings, together with prior observations in human tumor specimens (Zhou et al., 2003) , implicate PP2A Ab as a tumor suppressor gene.
Somatic mutations of the PP2A structural Aa subunit have also been reported in human cancers (Calin et al., 2000; Ruediger et al., 2001b) . Although these distinct PP2A A isoforms, a and b, are 86% identical (Hendrix et al., 1993) , it remained unclear whether these two isoforms are functionally interchangeable (Gotz et al., 2000) . We previously showed that near complete suppression of PP2A Aa subunit expression induced cell death by apoptosis while cancer-associated PP2A Aa mutations contributed to human cell transformation by creating a state of haploinsufficiency . In contrast, loss-of-function of both Ab alleles leads to human cell transformation. These observations are consistent with prior studies, which showed that mutations of the Aa gene occur on one allele while alterations of the Ab gene are found in both alleles (Wang et al., 1998) . Here we also found that the Aa isoform cannot functionally substitute for Ab. Consistent with prior observations, we also found that only the Aa isoform interacts SV40 ST, suggesting that the transformed phenotype induced by suppression of Ab occurs by distinct mechanism from that induced by expression of ST. Collectively, these observations indicate that PP2A complexes containing Aa or Ab are functionally distinct and contribute to cell transformation by discrete mechanisms (Figure 6 ).
PP2A Ab Binds and Regulates the Small GTPase RalA
Here we show that PP2A Ab interacts with and modulates the activity of the small GTPase RalA. RalA is a multifunctional protein, regulating membrane transport, apoptosis, transcription, cell migration and cell proliferation [reviewed in (Camonis and White, 2005; Feig, 2003) ]. RalA activation results in activation of several signaling pathways, including the activation of phospholipase D1 and Src kinase (Goi et al., 2000; Jiang et al., 1995) , vesicle transport (Moskalenko et al., 2002) , filopodia formation (Ohta et al., 1999) , epidermal growth factor-induced cell motility (Gildea et al., 2002) and AI growth (Chien and White, 2003; Lim et al., 2005; Panner et al., 2006) . The activation of known RalA effector proteins such as RalBP1 or the exocyst has not previously been directly linked to tumorigenesis. However, other signaling molecules regulated by RalA, such as phospholipase D1, Src, JNK, NF-kB and cyclin D, may contribute to cancer progression (Feig, 2003; Lim et al., 2005) .
Consistent with prior reports, we observed that RalA suppression diminished the ability of transformed cells to form AI colonies (Chien and White, 2003; Lim et al., 2005) . Strikingly, RalA depletion in cells lacking Ab completely abolishes AI growth, indicating that RalA is necessary for transformation induced by suppression of Ab. Furthermore, we found that cancer-derived Ab mutants fail to form complexes with RalA protein. Since Ab mutations occur throughout its coding sequence, we speculate that these cancer-associated mutations fail to bind RalA due to disruption of functional heterotrimeric PP2A Ab complexes rather than through specific interactions with these mutant residues. This model is consistent with recent structural determinations of the PP2A Aa complex (Cho and Xu, 2007; Xu et al., 2006) . Functionally, these Ab mutants thus fail to down-regulate RalA resulting in the increased RalA activity observed in cells lacking functional Ab complexes.
We also found accumulation of RalA phosphorylated at Ser183/Ser194 in cells lacking Ab expression, suggesting that RalA activity can be modulated by (de)phosphorylation. Prior studies have identified two pathways to activate RalA. The cycling of RalA between GDP and GTP bound forms is regulated by guanine nucleotide exchange factors (GEFs), which promote GTP binding, and GTPase activating proteins, which promote GTP hydrolysis (Feig, 2003; Quilliam et al., 2002) . At least four RalGEFs are known which are stimulated by activated RAS. Moreover, several GAPs down-regulate RalA (Emkey et al., 1991) . In addition, the elevation of intracellular Ca 2+ levels and interaction of RalA with calmodulin also enhances the binding of GTP to RalA in vitro [reviewed in (Feig, 2003; van Dam and Robinson, 2006) ]. Together, these observations identify phosphorylation of RalA as another mechanism that regulates RalA activity and cell transformation.
A prior report demonstrated that the phosphorylation of the RAS family members Rap1a and Rap1b proteins occurs at C-terminal residues Ser180 or Ser179, respectively. This change in phosphorylation modulates the ability of Rap1a to associate and regulate its downstream targets (Altschuler and Lapetina, 1993; Hu et al., 1999; Quilliam et al., 1991) . RalA has also been shown to be phosphorylated at Ser194 by Aurora kinase A (Wu et al., 2005) . Here we have identified two additional RalA phosphorylation sites -Ser11 and Ser183. Using alanine substitution Ab mutants, we identified S183 and S194 as residues dephosphoryalted by PP2A Ab and required for the interaction of RalA and PP2A Ab. Although PP2A Ab is likely to have other substrates in addition to RalA, the regulation of RalA phosphorylation appears to play a critical role in transformation associated with loss of functional Ab in human cancers. In agreement with these findings, overexpression of Aurora A kinase was shown to increase the amount of GTP-bound RalA, thereby promoting collagen I-induced migration and AI growth in MDCK cells (Wu et al., 2005) . Thus, the phosphorylation of RalA at Ser183 and Ser194 may represent a RAS-independent mechanism of RalA regulation; however, further studies are required to identify the kinase(s) that are responsible for RalA phosphorylation at these sites.
PP2A Ab, RalA, and Human Cell Transformation Several recent studies implicate the activation of RalA in cell transformation. In HEK cells expressing LT, ST and hTERT, substitution of an oncogenic allele of H-RAS with a Ras effector mutant that binds selectively to RalGEFs (RAS V12, G37) led to AI growth. However, in these experiments, the additional expression of Ras mutants that bind either Raf (RAS V12, S35) or PI3K (RAS V12, C40) was necessary to achieve tumorigenicity (Hamad et al., 2002; Rangarajan et al., 2004) , indicating that the activation of RalGEFs contributes to but does not suffice to substitute for RAS. Furthermore, overexpression of constitutively-activated forms of RalA (G23V or Q72L) induces AI growth of immortalized HEK cells and human fibroblasts expressing LT, ST and hTERT (Lim et al., 2005) . These observations implicate the activation of RalGEFs as an important Ras effector pathway in human cells.
Here we demonstrate that suppression of PP2A Ab leads to RalA activation, which substitutes for ST expression to induce both AI growth and tumorigenicity in human cells expressing LT, hTERT and H-RAS. Together with our prior observations that implicated PI3K signaling as a target of B56g suppression or ST expression (Chen et al., 2004; Zhao et al., 2003) , these findings confirm that the pathways activated by ST and H-RAS are highly overlapping. Consistent with these observations, constitutively active forms of RalA cooperate with H-RAS or Raf to induce cell transformation (Urano et al., 1996) . Indeed, we and others have found that expression of a degradation resistant form of c-Myc (Yeh et al., 2004) or expression of an activated allele of PI3K (Zhao et al., 2003) also substitute for ST in human cell transformation. Further studies are necessary to determine whether these effector pathways induce particular transformation phenotypes that are not adequately assessed in standard in vitro transformation assays or whether the activation of multiple RAS effector pathways is necessary to bypass regulatory feedback loops normally induced by physiological Ras signaling.
Although the specific targets of RalA critical for cell transformation are not yet known, elevated levels of GTP-bound RalA have been reported in pancreatic cancer cell lines (Lim et al., 2005 (Lim et al., , 2006 , and we found that lung cancer cell lines lacking functional PP2A Ab exhibit elevated levels of activated RalA. Thus, the activation of RalA may represent one critical downstream effector of RAS signaling, one that is regulated by the antagonistic actions of proto-oncogenes such as RAS and tumor suppressor genes such as PP2A Ab.
These observations establish PP2A Ab as a serine threonine phosphatase tumor suppressor gene that contributes to cell transformation by regulating the phosphorylation status and activity of RalA. Moreover, since PP2A complexes composed of PP2A Aa and Ab regulate different signaling pathways, these observations challenge the view that phosphatases act promiscuously and constitutively. Instead these findings suggest that phosphatases such as PP2A regulate specific phosphorylation events necessary for the initiation and/or maintenance of tumors. Thus, elucidating the role of PP2A and other phosphatases in these processes is likely to provide further insights into cell transformation and identify additional cancer targets.
EXPERIMENTAL PROCEDURES
Protein Phosphatase Activity
The protein phosphatase activity in immune complexes was determined as described (Chen et al., 2004) . For measuring phosphatase activity in whole cell lysates, and free phosphate was first removed from cell lysates by passage through a Sephadex G-25 column (Amersham, Piscataway, NJ). Serine/threonine phosphatase activity in these cell lysates was then measured by the capacity to dephosphorylate a synthetic phosphothreonine peptide RRA(pT)VA specific for PP2A. Specificity was confirmed using purified PP2A core enzyme in the presence or absence of 5 nM OA. After 30 min incubation at RT, free phosphate was measured colorimetrically.
Proliferation, AI Growth, and Tumor Formation 1310 4 cells were plated in triplicate and counted every 4 d. For population doublings, a seeding density of 1310 4 cells in a 10-cm plate was used for all cultures. Soft agar and tumorigenicity assays were performed as described (Hahn et al., 1999) . AI colonies were counted 4 wk after seeding at 103 magnification. The number of tumors formed was determined 40 d after injection.
RalA Activation Assay
The RalA activation assay was performed using RalA activation kit (Upstate Biotechnology, Lake Placid, NY). Cell lysates (2 mg) were precleared with glutathione agarose (Amersham Biosciences, Piscataway, NJ) and then incubated with 20 ml of RalBP1 agarose for 1 hr. The beads were washed, and the samples were subjected to 12% SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with an anti-RalA antibody (BD Biosciences, San Jose, CA).
Generation of Phosphospecific RalA Antibodies
To generate phosphospecific antibodies, 6 mice were immunized with two KLH-conjugated phospho-peptides (phospho-Ser183 and phospho-Ser194). After 3 immunizations, murine sera from 5 mice were tested by immunoblotting KLH-conjugated phosphorylated RalA peptides. Hybridomas were generated from one of these mice; 1000 supernatants were tested by ELISA; and the 13 positive supernatants were then analyzed by immunoblotting RalA phospho-peptides. We used the sera from the positive immunized mice and the supernatant from one positive parental line, XL13.
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